Biocon rises as its arm gets USFDA’s nod for Norepinephrine Bitartrate Injection

24 Mar 2025 Evaluate

Biocon is currently trading at Rs. 350.55, up by 6.60 points or 1.92% from its previous closing of Rs. 343.95 on the BSE.

The scrip opened at Rs. 348.10 and has touched a high and low of Rs. 351.85 and Rs. 345.50 respectively. So far 21943 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 404.60 on 21-Jan-2025 and a 52 week low of Rs. 248.90 on 22-Mar-2024.

Last one week high and low of the scrip stood at Rs. 351.85 and Rs. 323.20 respectively. The current market cap of the company is Rs. 42123.05 crore.

The promoters holding in the company stood at 60.64%, while Institutions and Non-Institutions held 21.02% and 18.34% respectively.

Biocon’s wholly owned subsidiary -- Biocon Pharma has received approval from the U.S Food and Drug Administration (USFDA) for its ANDA Norepinephrine Bitartrate Injection USP, 4 mg/4 mL (1 mg/mL) single-dose vial. Norepinephrine bitartrate injection is indicated to raise blood pressure in adult patients with acute hypotension. The approval further adds to Biocon’s portfolio of complex drug products.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

Biocon Share Price

344.65 -3.65 (-1.05%)
27-Mar-2025 13:33 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1724.35
Dr. Reddys Lab 1155.10
Cipla 1467.80
Lupin 2024.30
Zydus Lifesciences 890.10
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
Please wait your portfolio is updating...